AgelessRx provides anti-aging treatments supported by longevity science. The organization offers various therapies to assist individuals in managing health concerns related to aging.

AgelessRx

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics, Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Eric Morgan

Eric Morgen

BioAge Labs, Inc. Common Stock

Biosplice is a company that develops therapies using alternative splicing technology to restore health. The company focuses on creating treatments that harness alternative splicing in human DNA to address various medical conditions.

Metric
Company Name	AgelessRx	Anika Therapeutics, Inc.	BioAge Labs, Inc. Common Stock	Biosplice
Symbol		ANIK	BIOA
MSH ID	COM:AGELESSRX	COM:ANIKA	COM:BIOAGELABS	COM:BIOSPLICE
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare		Healthcare & Health Services
Industry	Medical Services	Medical - Devices		Biotechnology
Country	US	US	US	US
Stage
Employee Count		357
Website	agelessrx.com	anikatherapeutics.com	bioagelabs.com	biosplice.com
LinkedIn			bioage-labs	biospliceinc
Founders

Metric
Market Cap	389.26M	658.54M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		166.66M
Revenue (LTM)
Revenue (NTM)
Gross Profit		103.09M
EBITDA		-11.21M
Operating Income		-25.45M
Net Income		-82.67M
EPS		-5.64
Diluted EPS		-5.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.62
Operating Profit Margin		-0.08
EBITDA Margin		-0.07
Net Profit Margin		-0.44
Return on Equity		-0.32
Return on Assets		-0.28
Return on Capital Employed		-0.06

AGEL

COM:AGELESSRX

AgelessRx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-14.02
P/B Ratio		1.27
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		2.52
EV Multiple		-28.38

Metric
Days Sales Outstanding		77.51
Days Payables Outstanding		48.25
Days Inventory Outstanding		295.29
Operating Cycle		369.15
Cash Conversion Cycle		311.81
Asset Turnover		0.64

Metric
Operating Cash Flow		-1.79M
Free Cash Flow		-7.21M
Cash Flow to Debt		0.32
Operating Cash Flow/Sales		0.05
Free Cash Flow Yield		-0.03

Metric
Cash & Equivalents		72.87M
Accounts Receivable		-1.30M
Inventory		46.39M
Goodwill		7.57M
Debt to Capitalization		0.12
Debt to Assets		0.08
Current Ratio		5.59
Quick Ratio		3.96

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.09
R&D to Revenue		0.20
SG&A to Revenue